UPB NASDAQ
Upstream Bio, Inc.
1W: -1.1%
1M: -47.4%
3M: -56.5%
YTD: -89.3%
1Y: -83.0%
$2.79
+0.04 (+1.45%)
Weekly Expected Move ±13.6%
$2
$2
$3
$3
$3
Credit Risk of going bust: higher than 55% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.8%), Upstream Bio, Inc. would be worth roughly what it owes.
Total debt $954K against a stock market value of $152.8M.
Distance to default 4.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $841K (short-term plus half of long-term), stock volatility 102.1%; Altman Z'' 25.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.8%), Upstream Bio, Inc. would be worth roughly what it owes.
Total debt $954K against a stock market value of $152.8M.
Distance to default 4.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $841K (short-term plus half of long-term), stock volatility 102.1%; Altman Z'' 25.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$152.8M
52W Range2.68-33.68
Volume1,179,620
Avg Volume739,308
Beta1.39
Dividend—
Analyst Ratings
Company Info
CEOE. Rand Sutherland
Employees75
SectorHealthcare
IndustryBiotechnology
IPO Date2024-10-11
Websiteupstreambio.com
890 Winter Street
Waltham, MA 02451
US
Waltham, MA 02451
US
781 208 2466
About Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Latest News
At a glance: stocks gapping up premarket
Upstream Bio stock jumps 8% on Phase 2 severe asthma data
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
HC Wainwright Reduces Earnings Estimates for Upstream Bio
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| GRAY MICHAEL | S-Sale | 853 | $5.49 | 2026-09-16 |
| Ambrose Allison | S-Sale | 485 | $5.49 | 2026-09-16 |
| Deykin Aaron | S-Sale | 895 | $5.49 | 2026-09-16 |
| Sutherland Everett R | S-Sale | 2,095 | $5.49 | 2026-09-16 |
| Houghton Adam | S-Sale | 700 | $5.49 | 2026-09-16 |